Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

119 views

Published on

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy).- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

  • Hi! Get Your Professional Job-Winning Resume Here! 👉 http://bit.ly/rexumtop
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H22012Published on September 2012 Report SummaryPeripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012SummaryGlobal Markets Directs, Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012, provides an overview of theindications therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (SensoryNeuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (SensoryNeuropathy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietarydatabases, Company/University websites, SEC filings, investor presentations and featured press releases from company/universitysites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicateddisease.Scope- A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/researchinstitutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (SensoryNeuropathy).- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitiveadvantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth andfocus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects toenhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 1/6
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Peripheral Neuropathy (Sensory Neuropathy) Overview 7Therapeutics Development 8An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) 8Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Companies 10Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes 11Late Stage Products 13Comparative Analysis 13Mid Clinical Stage Products 14Comparative Analysis 14Discovery and Pre-Clinical Stage Products 15Comparative Analysis 15Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Products under Development by Companies 16Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Products under Investigation by Universities/Institutes 17Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development 18NsGene A/S 18Neuren Pharmaceuticals Limited 19NeurogesX, Inc. 20Allon Therapeutics Inc. 21Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Assessment 22Assessment by Monotherapy Products 22Assessment by Combination Products 23Assessment by Route of Administration 24Assessment by Molecule Type 26Drug Profiles 28capsaicin - Drug Profile 28Product Description 28Mechanism of Action 28R&D Progress 28AL-309 - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29NNZ-2591 - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30NsG-31 - Drug Profile 32Product Description 32Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 2/6
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Mechanism of Action 32R&D Progress 32amifostine - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33Amitriptyline + Ketamine - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34glutamine - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35Carboplatin + Glutathione + Paclitaxel - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36thioctic acid [JAN] - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38Immunoglobulin - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39flupirtine maleate - Drug Profile 40Product Description 40Mechanism of Action 40R&D Progress 40Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Drug Profile Updates 41Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Discontinued Products 43Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 44Peripheral Neuropathy (Sensory Neuropathy) Product Development Milestones 45Featured News & Press Releases 45Nov 17, 2011: Pfizer Obtains European Approval For Vyndaqel For Transthyretin Familial Amyloid Polyneuropathy 45Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 46Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced PeripheralNeuropathy 47Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral NeuropathyAnd Advanced Cancer 48Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress OnNeuropathic Pain In Athens, Greece 49Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations. 49Dec 20, 2009: CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference in San Francisco 50Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference 50Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 3/6
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Appendix 51Methodology 51Coverage 51Secondary Research 51Primary Research 51Expert Panel Validation 51Contact Us 52Disclaimer 52List of TablesNumber of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8Products under Development for Peripheral Neuropathy (Sensory Neuropathy) Comparative Analysis, H2 2012 9Number of Products under Development by Companies, H2 2012 10Number of Products under Investigation by Universities/Institutes, H2 2012 12Comparative Analysis by Late Stage Development, H2 2012 13Comparative Analysis by Mid Clinical Stage Development, H2 2012 14Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15Products under Development by Companies, H2 2012 16Products under Investigation by Universities/Institutes, H2 2012 17NsGene A/S, H2 2012 18Neuren Pharmaceuticals Limited, H2 2012 19NeurogesX, Inc., H2 2012 20Allon Therapeutics Inc., H2 2012 21Assessment by Monotherapy Products, H2 2012 22Assessment by Combination Products, H2 2012 23Assessment by Stage and Route of Administration, H2 2012 25Assessment by Stage and Molecule Type, H2 2012 27Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Drug Profile Updates 41Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Discontinued Products 43Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Dormant Products 44List of FiguresNumber of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8Products under Development for Peripheral Neuropathy (Sensory Neuropathy) Comparative Analysis, H2 2012 9Products under Development by Companies, H2 2012 10Products under Investigation by Universities/Institutes, H2 2012 11Late Stage Products, H2 2012 13Mid Clinical Stage Products, H2 2012 14Discovery and Pre-Clinical Stage Products, H2 2012 15Assessment by Monotherapy Products, H2 2012 22Assessment by Combination Products, H2 2012 23Assessment by Route of Administration, H2 2012 24Assessment by Stage and Route of Administration, H2 2012 25Assessment by Molecule Type, H2 2012 26Assessment by Stage and Molecule Type, H2 2012 27Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 4/6
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 5/6
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review, H2 2012 (From Slideshare) Page 6/6

×